Ontology highlight
ABSTRACT:
SUBMITTER: Buseman CM
PROVIDER: S-EPMC3375693 | biostudies-literature | 2012 Feb
REPOSITORIES: biostudies-literature
Buseman C M CM Wright W E WE Shay J W JW
Mutation research 20110723 1-2
The ideal cancer treatment would specifically target cancer cells yet have minimal or no adverse effects on normal somatic cells. Telomerase, the ribonucleoprotein reverse transcriptase that maintains the ends of human chromosome, is an attractive cancer therapeutic target for exactly this reason [1]. Telomerase is expressed in more than 85% of cancer cells, making it a nearly universal cancer marker, while the majority of normal somatic cells are telomerase negative. Telomerase activity confers ...[more]